BR112023020979A2 - Moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los - Google Patents

Moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los

Info

Publication number
BR112023020979A2
BR112023020979A2 BR112023020979A BR112023020979A BR112023020979A2 BR 112023020979 A2 BR112023020979 A2 BR 112023020979A2 BR 112023020979 A BR112023020979 A BR 112023020979A BR 112023020979 A BR112023020979 A BR 112023020979A BR 112023020979 A2 BR112023020979 A2 BR 112023020979A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
methods
taar1
serotonin modulators
pharmaceutically acceptable
Prior art date
Application number
BR112023020979A
Other languages
English (en)
Inventor
Julian Hodgetts Kevin
Linghong Xie
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of BR112023020979A2 publication Critical patent/BR112023020979A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los. trata-se de um composto da fórmula i:, ou um sal farmaceuticamente aceitável do mesmo, em que os valores para as variáveis (por exemplo, r1, r2, x1, x2, y1, y2, y3, y4, y5, y6, y7 e y8) são conforme revelado no presente documento. no presente documento, também são fornecidas composições farmacêuticas que compreendem um composto da fórmula i, ou um sal farmaceuticamente aceitável do mesmo, e métodos para usar os compostos, sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas dos supracitados, por exemplo, para tratar uma doença ou distúrbio neurológico ou psiquiátrico.
BR112023020979A 2021-04-10 2022-04-08 Moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los BR112023020979A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163173368P 2021-04-10 2021-04-10
PCT/US2022/071613 WO2022217265A1 (en) 2021-04-10 2022-04-08 Taar1 and serotonin modulators, and pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023020979A2 true BR112023020979A2 (pt) 2023-12-12

Family

ID=83546636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020979A BR112023020979A2 (pt) 2021-04-10 2022-04-08 Moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los

Country Status (10)

Country Link
EP (1) EP4319738A1 (pt)
JP (1) JP2024513500A (pt)
KR (1) KR20230170016A (pt)
CN (1) CN117279632A (pt)
AU (1) AU2022253074A1 (pt)
BR (1) BR112023020979A2 (pt)
CA (1) CA3215043A1 (pt)
IL (1) IL307502A (pt)
TW (1) TW202304872A (pt)
WO (1) WO2022217265A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
EP3661929B1 (en) * 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof

Also Published As

Publication number Publication date
JP2024513500A (ja) 2024-03-25
IL307502A (en) 2023-12-01
CA3215043A1 (en) 2022-10-13
EP4319738A1 (en) 2024-02-14
WO2022217265A1 (en) 2022-10-13
CN117279632A (zh) 2023-12-22
KR20230170016A (ko) 2023-12-18
AU2022253074A1 (en) 2023-10-12
TW202304872A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
EA201070143A1 (ru) Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
BRPI0516340A (pt) composto, composição farmacêutica, método para tratar uma condição que é regulada ou normalizada via inibição de dpp-iv, método para tratar um distúrbio metabólico, método para tratar diabete tipo ii, método para diminuir glicose no sangue, método para tratamento e profilaxia de uma doença, método para tratar toleráncia não prejudicada a glicose insulino-resistente, método para a manufatura de uma composição farmacêutica e processo para a preparação de compostos
BR112015022575A2 (pt) composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
BRPI0511072B8 (pt) compostos derivados de alquinila como moduladores dos receptores de glutamato metabotróbico, seus usos e suas composições farmacêuticas
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112014009717A2 (pt) "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica"
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112012025590A2 (pt) análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
BR112022020291A2 (pt) Inibidores de cd38
MX2022000164A (es) Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos.
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
BR112022006572A2 (pt) Inibidores orais do fator d do complemento
BR112023012947A2 (pt) Inibidores de lrrk2
BR112012022224A2 (pt) compostos úteis tratar distúrbios neurodegenerativos
BR112023020979A2 (pt) Moduladores de taar1 e de serotonina e composições farmacêuticas e métodos para usá-los
BRPI0915627A8 (pt) Compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
AR123281A1 (es) Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização